KiDSafe - Improving medication safety for children and adolescents: implementation and evaluation of a new form of care
Not Applicable
- Conditions
- Quality assurance procedure to increase the safety of drug therapy for children and adolescents
- Registration Number
- DRKS00013924
- Lead Sponsor
- Konsortialführung: Universitätsklinikum Erlangen, Kinder- und Jugendklinik
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 41829
Inclusion Criteria
non-elective admitted patients, who are less than 18 years of age at the time of admission
Exclusion Criteria
oncological patients who are hospitalized with suspected ADR/ME and who have been hospitalized in the previous 4 weeks for oncological
treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of drug-related hospital admissions
- Secondary Outcome Measures
Name Time Method Prescribing and reporting behavior of outpatient doctors<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie pediatric medication safety improvements in KiDSafe's interventional care model?
How does KiDSafe's protocol compare to standard-of-care in reducing adverse drug events for children?
Which biomarkers are used in KiDSafe to predict therapeutic response in pediatric drug therapy?
What adverse event management strategies are implemented in DRKS00013924's pediatric medication safety trial?
Are there combination therapies or competitor protocols addressing pediatric pharmacovigilance similar to KiDSafe?